Annual Report 2020
Department of Gastric Surgery
Takaki Yoshikawa, Yukinori Yamagata, Tsutomu Hayashi, Takeyuki Wada, Mai Tsutsui
Introduction
Our division provides surgical treatment for patients with gastric cancer, adenocarcinoma of the esophago-gastric junction, and gastrointestinal stromal tumors (GIST). The aim of our division is to contribute to human health through treatment and research in this field. Our policy to achieve this goal is to (1) provide high-quality treatment for patients, (2) perform our clinical tasks efficiently, and (3) contribute to developing treatments through clinical trials and research and to provide high-quality education.
The Team and What We Do
(1) To provide high-quality treatment, we conduct daily morning conference to determine the treatment strategy for new patients and patients who require new treatments. All staff members check endoscopy and CT results and determine the tumor staging based on uniform criteria. The team then discusses the treatment strategy for each patient based on the problem at hand when applying standard treatment and whether the patient is a candidate for a particular clinical trial. After introducing the Enhanced Recovery After Surgery (ERAS) program for perioperative care, we saw a dramatic reduction in surgical morbidity and hospital stays.
(2) To perform our clinical tasks efficiently, we prepare patients' medical documents for the uniform explanation and the printed protocols in the conference room and the out-patient clinic to check patients' eligibility for clinical trials. We also relieve the physicians and residents from having to prepare the database.
(3) Our division managed a total 249 cases this year, including gastric cancer, GIST, and others (Table 1). Detailed surgical procedure is shown in Table 2. The proportion of laparoscopic surgery has increased year by year; from 49% (2017) to 65% (2018), 62% (2019), and 62% (2020) for distal/pylorus-preserving gastrectomy and from 12% (2017) to 21% (2018), 44% (2019), and 37% (2020) of total/proximal gastrectomy. In particular, we managed 14 cases of RA-distal gastrectomy and 5 cases of proximal gastrectomy with no morbidity. Cases of extended surgery were not rare. There were numerous cases of D2 plus para-aortic nodal dissection after neoadjuvant chemotherapy for bulky nodal disease and para-aortic nodal metastasis, as well as several cases of left upper abdominal exenteration for bulky GIST invading adjacent organs and lower mediastinal dissection using a trans-hiatal approach and a video-assisted right trans-thoracic approach for gastric cancer invading the lower esophagus. We provide all types of surgery for local control, as applicable. Figure 1 shows the overall survival curves for the 6532 patients who underwent surgery between 2000 and 2015. The overall survival rate at 5 years was 95.6% for stage IA, 92.8% for stage IB, 88.3% for stage IIA, 80.5% for stage IIB, 65.6% for stage IIIA, 55.4% for stage IIIB, 32.9% for stage IIIC, and 16.2% for stage IV, following the 15th edition of the Japanese Classification of Gastric Cancer.
Figure 1. Overall survival curves of patients who have undergone resection (2000-2015, n=6532)
Research activities
We publish many quality papers in English, more than 7 as the corresponding author and more than 25 as co-authors.
Clinical trials
On the JCOG trial, we continued to recruit new patients to JCOG1507 phase III (surgery alone vs S-1 for elderly patients with pathological stage II/III gastric cancer), JCOG1509 phase III (surgery followed by adjuvant chemotherapy vs. neoadjuvant chemotherapy with S-1/oxaliplatin followed by surgery and adjuvant chemotherapy for patients with SS/SE gastric cancer invading the lymph nodes), JCOG1704 phase II (neoadjuvant chemotherapy of DOS followed by D2 plus para-aortic nodal dissection and adjuvant chemotherapy), JCOG1711 phase III (omentectomy vs. omental preservation for SS/SE gastric cancer), JCOG1809 phase II (laparoscopic splenic hilar nodal dissection for upper gastric cancer invading the greater curvature), and JCOG1902 phase III (laparoscopic vs. robotic gastrectomy for clinical stage I/IIA gastric cancer). We followed-up the patients who had enrolled in the following: JCOG1010 single-arm phase III (ESD for undifferentiated type), JCOG1104 phase III (8 courses S-1 vs. 4 courses S-1 for stage II), JCOG1301C randomized phase II (neoadjuvant chemotherapy of S-1/CDDP with or without trastuzumab for HER2-positive gastric cancer invading the lymph nodes), and JCOG1401 single-arm phase III (laparoscopic total / proximal gastrectomy for stage I). We also published a protocol paper for the JCOG1711 phase III study in Jpn J Clin Oncol (IF: 1.914) and the primary results of the JCOG0501 phase III study to compare surgery and adjuvant S-1 with or without neoadjuvant chemotherapy of S-1/CDDP for type 4 and giant type 3 gastric cancer in Gastric Cancer (IF: 7.664).
In our collaborative research with England, the Netherlands, Singapore, and Germany, we published several papers in Gastric Cancer (IF: 7.664) and Journal of Pathol Clin Res Cancer (IF: 3.426).
This year, we started the safety lead-in part of a global phase III study to confirm the efficacy of durvalumab, a new PDL-1 antibody, in addition to FLOT, a western standard perioperative chemotherapy for stage II/III gastric cancer.
Education
Through open conferences to determine the tumor staging and treatment strategies, the trainees can study the standard treatment, the problems in applying the standard therapy, and the treatment being researched. They can also gain experience a first/second assistants to surgery performed by experienced staff, as scopists for laparoscopic surgery, and even operators under instruction by experienced staff. To obtain the endoscopic surgeon certification, trainees can gain experience with animal models and receive video reviews by experienced staff. Following the success of past residents, this year's chief resident passed the endoscopic surgeon certification, despite a pass rate for the examination of approximately 20%. Our department's pass rate has been over 80% since 2018.
Young surgeons can also continue their clinical research and publish their papers in the following English journals; Gastric Cancer (IF: 7.088), Surg Case Rep, Ann Gastroenterol Surg (IF: 5.164), World J Surg Oncol (IF: 0.757), BMC Surg (IF: 1.952), and Surgery Today (IF: 1.878).
Future Prospects
We will continue providing high-quality treatment, efficiency in our clinical tasks, clinical trials and research, and education in the field of gastric surgery, thereby contributing to human health.
List of papers published in 2020
Journal
1. Kamiya A, Katai H, Ishizu K, Wada T, Hayashi T, Otsuki S, Yamagata Y, Yoshikawa T, Sekine S, Nishi T, Kawasaki Y, Ito T, Domoto H. Recurrence after ESD curative resection for early gastric cancer. Surg Case Rep, 7:5, 2021
2. Hayashi M, Yoshikawa T, Yura M, Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T. Intraoperative blood loss as an independent prognostic factor for curative resection after neoadjuvant chemotherapy for gastric cancer: a single-center retrospective cohort study. Surg Today, 51:293-302, 2021
3. Abe S, Takizawa K, Oda I, Mizusawa J, Kadota T, Ono H, Hasuike N, Yano T, Yamamoto Y, Horiuchi Y, Nagata S, Yoshikawa T, Terashima M, Muto M. Incidence and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection of undifferentiated-type early gastric cancer: Japan Clinical Oncology Group study-post hoc analysis of JCOG1009/1010. Gastric Cancer, 2021
4. Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Nishiyama T, Chen LT, Kang YK. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer, 24:946-958, 2021
5. Murakami H, Yamada T, Taguri M, Hasegawa S, Yamanaka T, Rino Y, Mushiake H, Oshima T, Matsukawa H, Tani K, Suzuki Y, Ozawa Y, Tanabe H, Osaragi T, Sato T, Tamagawa H, Yukawa N, Yoshikawa T, Imada T, Masuda M, Yamamoto Y. Short-Term Outcomes from a Randomized Screening Phase II Non-inferiority Trial Comparing Omentectomy and Omentum Preservation for Locally Advanced Gastric Cancer: the TOP-G Trial. World J Surg, 45:1803-1811, 2021
6. Kano K, Yamada T, Yamamoto K, Komori K, Watanabe H, Takahashi K, Maezawa Y, Fujikawa H, Numata M, Aoyama T, Tamagawa H, Cho H, Yukawa N, Yoshikawa T, Rino Y, Masuda M, Ogata T, Oshima T. Evaluation of Lymph Node Staging Systems as Independent Prognosticators in Remnant Gastric Cancer Patients with an Insufficient Number of Harvested Lymph Nodes. Ann Surg Oncol, 28:2866-2876, 2021
7. Kawazoe A, Shitara K, Boku N, Yoshikawa T, Terashima M. Current status of immunotherapy for advanced gastric cancer. Jpn J Clin Oncol, 51:20-27, 2021
8. Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito S, Kaji M, Kimura Y, Hirao M, Yamada M, Kurita A, Takagi M, Lee SW, Takagane A, Yabusaki H, Hihara J, Boku N, Sano T, Sasako M. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer, 24:492-502, 2021
9. Cho H, Yamada M, Sekine S, Tanabe N, Ushiama M, Hirata M, Ogawa G, Gotoh M, Yoshida T, Yoshikawa T, Saito Y, Kuchiba A, Oda I, Sugano K. Gastric cancer is highly prevalent in Lynch syndrome patients with atrophic gastritis. Gastric Cancer, 24:283-291, 2021
10. Tokunaga M, Kurokawa Y, Machida R, Sato Y, Takiguchi S, Doki Y, Yabusaki H, Watanabe M, Hato S, Nakamori M, Ito S, Yoshikawa T, Terashima M. Impact of postoperative complications on survival outcomes in patients with gastric cancer: exploratory analysis of a randomized controlled JCOG1001 trial. Gastric Cancer, 24:214-223, 2021
11. Fujitani K, Nakamura K, Mizusawa J, Kuwata T, Shimoda T, Katayama H, Kushima R, Taniguchi H, Yoshikawa T, Boku N, Terashima M, Fukuda H, Sano T, Sasako M. Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A. Gastric Cancer, 24:197-204, 2021
12. Abe S, Matsuzaki J, Sudo K, Oda I, Katai H, Kato K, Takizawa S, Sakamoto H, Takeshita F, Niida S, Saito Y, Ochiya T. A novel combination of serum microRNAs for the detection of early gastric cancer. Gastric Cancer, 24:835-843, 2021
13. Yamaguchi T, Takashima A, Nagashima K, Terashima M, Aizawa M, Ohashi M, Tanaka R, Yamada T, Kinoshita T, Matsushita H, Ishiyama K, Hosoda K, Yuasa Y, Haruta S, Kakihara N, Nishikawa K, Yunome G, Satoh T, Fukagawa T, Katai H, Boku N. Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study. Gastric Cancer, 24:701-709, 2021
14. Tsuji Y, Ushiku T, Shinozaki T, Yamashita H, Seto Y, Fukayama M, Fujishiro M, Oda I, Katai H, Taniguchi H, Hasatani K, Kaizaki Y, Oga A, Nishikawa J, Akasaka R, Endo M, Sugai T, Matsumoto T, Koike K. Risk for lymph node metastasis in Epstein-Barr virus-associated gastric carcinoma with submucosal invasion. Dig Endosc, 33:592-597, 2021
15. Ito Y, Miyashiro I, Ishikawa T, Akazawa K, Fukui K, Katai H, Nunobe S, Oda I, Isobe Y, Tsujitani S, Ono H, Tanabe S, Fukagawa T, Suzuki S, Kakeji Y, Sasako M, Bilchik A, Fujita M. Determinant Factors on Differences in Survival for Gastric Cancer Between the United States and Japan Using Nationwide Databases. J Epidemiol, 31:241-248, 2021
16. Ishiyama K, Fujita T, Fujiwara H, Kurita D, Oguma J, Katai H, Daiko H. Does staged surgical training for minimally invasive esophagectomy have an impact on short-term outcomes? Surg Endosc, 2020
17. Yamagata Y, Yoshikawa T, Ishizu K, Kamiya A, Wada T, Hayashi T, Otsuki S, Katai H. Is lymph node dissection for neuroendocrine carcinoma of the stomach effective as it is for adenocarcinoma? Eur J Surg Oncol, 2020
18. Kamiya A, Yamagata Y, Yoshida H, Ishizu K, Wada T, Hayashi T, Otsuki S, Yoshikawa T, Katai H. Laparoscopic resection of a primary diaphragmatic schwannoma: a case report and literature review. BMC Surg, 20:289, 2020
19. Kanamori K, Yamagata Y, Honma Y, Date K, Wada T, Hayashi T, Otsuki S, Sekine S, Yoshikawa T, Katai H, Nishida T. Extra-gastrointestinal stromal tumor arising in the lesser omentum with a platelet-derived growth factor receptor alpha (PDGFRA) mutation: a case report and literature review. World J Surg Oncol, 18:183, 2020
20. Hayashi M, Yoshikawa T, Yura M, Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T. Predictive value of the surgical Apgar score on postoperative complications in advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by radical gastrectomy: a single-center retrospective study. BMC Surg, 20:150, 2020
21. Hayashi T, Yoshikawa T, Kamiya A, Date K, Wada T, Otsuki S, Yamagata Y, Katai H, Nishida T. Is splenectomy for dissecting splenic hilar lymph nodes justified for scirrhous gastric cancer? Gastric Cancer, 23:922-926, 2020
22. Wada T, Yoshikawa T, Kamiya A, Date K, Hayashi T, Otsuki S, Yamagata Y, Katai H, Nishida T. A nodal diagnosis by computed tomography is unreliable for patients who need additional gastrectomy after endoscopic submucosal dissection. Surg Today, 50:1032-1038, 2020
23. Hayashi T, Yoshikawa T, Sakamaki K, Nishikawa K, Fujitani K, Tanabe K, Misawa K, Matsui T, Miki A, Nemoto H, Fukunaga T, Kimura Y, Hihara J. Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for advanced gastric cancer. Ann Gastroenterol Surg, 4:540-548, 2020
24. Oshima T, Yoshikawa T, Miyagi Y, Morita S, Yamamoto M, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Yokose T, Hiroshima Y, Aoyama T, Hayashi T, Ogata T, Cho H, Rino Y, Masuda M, Tsuburaya A, Sakamoto J. Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial. Oncotarget, 11:2906-2918, 2020
25. Sato Y, Yamada T, Yoshikawa T, Machida R, Mizusawa J, Katayama H, Tokunaga M, Boku N, Terashima M. Randomized controlled Phase III trial to evaluate omentum preserving gastrectomy for patients with advanced gastric cancer (JCOG1711, ROAD-GC). Jpn J Clin Oncol, 50:1321-1324, 2020
26. Maezawa Y, Aoyama T, Ju M, Komori K, Kano K, Sawazaki S, Numata M, Hayashi T, Yamada T, Tamagawa H, Sato T, Ogata T, Cho H, Oshima T, Yukawa N, Yoshikawa T, Masuda M, Rino Y. The Impact of Severe Infectious Complications on Long-term Prognosis for Gastric Cancer. Anticancer Res, 40:4067-4074, 2020
27. Meier A, Nekolla K, Hewitt LC, Earle S, Yoshikawa T, Oshima T, Miyagi Y, Huss R, Schmidt G, Grabsch HI. Hypothesis-free deep survival learning applied to the tumour microenvironment in gastric cancer. J Pathol Clin Res, 6:273-282, 2020
28. Kerckhoffs KGP, Liu DHW, Saragoni L, van der Post RS, Langer R, Bencivenga M, Iglesias M, Gallo G, Hewitt LC, Fazzi GE, Vos AM, Renaud F, Yoshikawa T, Oshima T, Tomezzoli A, de Manzoni G, Arai T, Kushima R, Carneiro F, Grabsch HI. Mucin expression in gastric- and gastro-oesophageal signet-ring cell cancer: results from a comprehensive literature review and a large cohort study of Caucasian and Asian gastric cancer. Gastric Cancer, 23:765-779, 2020
29. Kano K, Yamada T, Yamamoto K, Komori K, Watanabe H, Hara K, Shimoda Y, Maezawa Y, Fujikawa H, Aoyama T, Tamagawa H, Yamamoto N, Cho H, Shiozawa M, Yukawa N, Yoshikawa T, Morinaga S, Rino Y, Masuda M, Ogata T, Oshima T. Association Between Lymph Node Ratio and Survival in Patients with Pathological Stage II/III Gastric Cancer. Ann Surg Oncol, 27:4235-4247, 2020
30. Kumazu Y, Hayashi T, Yoshikawa T, Yamada T, Hara K, Shimoda Y, Nakazono M, Nagasawa S, Shiozawa M, Morinaga S, Rino Y, Masuda M, Ogata T, Oshima T. Risk factors analysis and stratification for microscopically positive resection margin in gastric cancer patients. BMC Surg, 20:95, 2020
31. Nishikawa K, Murotani K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Hasegawa H, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trial. Eur J Cancer, 132:159-167, 2020
32. Fujikawa H, Koumori K, Watanabe H, Kano K, Shimoda Y, Aoyama T, Yamada T, Hiroshi T, Yamamoto N, Cho H, Shiozawa M, Yoshikawa T, Morinaga S, Rino Y, Masuda M, Ogata T, Oshima T. The Clinical Significance of Lymphovascular Invasion in Gastric Cancer. In Vivo, 34:1533-1539, 2020
33. Shimoda Y, Yamada T, Komori K, Watanabe H, Osakabe H, Kano K, Fujikawa H, Hayashi T, Cho H, Shiozawa M, Yoshikawa T, Morinaga S, Ota Y, Katsumata K, Tsuchida A, Ogata T, Oshima T. Effect of Muscle Mass Loss After Esophagectomy on Prognosis of Oesophageal Cancer. Anticancer Res, 40:2275-2281, 2020
34. Sato Y, Mizusawa J, Katayama H, Nakamura K, Fukagawa T, Katai H, Haruta S, Yamada M, Takagi M, Tamura S, Yoshimura T, Tokunaga M, Yoshikawa T, Boku N, Sano T, Sasako M, Terashima M. Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: An exploratory analysis of Japan clinical oncology group study: JCOG1302A. Eur J Surg Oncol, 46:1074-1079, 2020
35. Terashima M, Yoshikawa T, Boku N, Ito S, Tsuburaya A, Iwasaki Y, Fukagawa T, Tokunaga M, Sano T, Sasako M. Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives. Jpn J Clin Oncol, 50:528-534, 2020
36. Kumazu Y, Oba K, Hayashi T, Yamada T, Hara K, Osakabe H, Shimoda Y, Nakazono M, Nagasawa S, Rino Y, Masuda M, Ogata T, Yoshikawa T, Oshima T. Relationship Between the Waiting Times for Surgery and Survival in Patients with Gastric Cancer. World J Surg, 44:1209-1215, 2020
37. Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer, 23:510-519, 2020
38. Hara K, Hayashi T, Nakazono M, Nagasawa S, Shimoda Y, Kumazu Y, Yamada T, Yamamoto N, Shiozawa M, Morinaga S, Yoshikawa T, Rino Y, Masuda M, Ogata T, Oshima T. An easy and reliable method to close Petersen's defect using barbed suture to prevent internal hernia from developing after gastrectomy with Roux-en-Y reconstruction. Asian J Endosc Surg, 13:238-241, 2020
39. Yang M, Arai E, Takahashi Y, Totsuka H, Chiku S, Taniguchi H, Katai H, Sakamoto H, Yoshida T, Kanai Y. Cooperative participation of epigenomic and genomic alterations in the clinicopathological diversity of gastric adenocarcinomas: significance of cell adhesion and epithelial-mesenchymal transition-related signaling pathways. Carcinogenesis, 41:1473-1484, 2020
40. Katai H, Ishikawa T, Akazawa K, Fukagawa T, Isobe Y, Miyashiro I, Oda I, Tsujitani S, Ono H, Tanabe S, Nunobe S, Suzuki S, Kakeji Y. Optimal extent of lymph node dissection for remnant advanced gastric carcinoma after distal gastrectomy: a retrospective analysis of more than 3000 patients from the nationwide registry of the Japanese Gastric Cancer Association. Gastric Cancer, 23:1091-1101, 2020
41. Takamaru H, Yoshinaga S, Takisawa H, Oda I, Katai H, Sekine S, Taniguchi K, Saito Y. Endoscopic Ultrasonography Miniature Probe Performance for Depth Diagnosis of Early Gastric Cancer with Suspected Submucosal Invasion. Gut Liver, 14:581-588, 2020
42. Sugawara K, Yoshimura S, Yagi K, Nishida M, Aikou S, Yamagata Y, Mori K, Yamashita H, Seto Y. Long-term health-related quality of life following robot-assisted radical transmediastinal esophagectomy. Surg Endosc, 34:1602-1611, 2020
43. Saito K, Yamagata Y, Hakozaki Y, Nakata M, Oya M. Early gastric cancer with splenic artery aneurysm successfully treated with laparoscopic distal gastrectomy after endovascular coil embolization: A case report. Asian J Endosc Surg, 2020
44. Nunobe S, Ri M, Yamazaki K, Uraoka M, Ohata K, Kitazono I, Terashima M, Yamagata Y, Tanabe S, Abe N, Tsuji T, Niimi K, Kawakubo H, Tsukada T, Kitashiro S, Ishizuka N, Hiki N. Safety and feasibility of laparoscopic and endoscopic cooperative surgery for duodenal neoplasm: a retrospective multicenter study. Endoscopy, 2020
45. Yamagata Y, Saito K, Hirano K, Oya M. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus. World J Surg Oncol, 18:252, 2020
46. Oneyama M, Sakamoto N, Oue N, Kimura Y, Hiroshima Y, Hashimoto I, Hara K, Maezawa Y, Kano K, Aoyama T, Fujikawa H, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Cho H, Ito H, Yukawa N, Shiozawa M, Yoshikawa T, Morinaga S, Rino Y, Masuda M, Miyagi Y, Yasui W, Oshima T. Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy. Anticancer Res, 39:6567-6573, 2019
47. Mori K, Ino K, Yoshimura S, Aikou S, Yagi K, Nishida M, Mitsui T, Okumura Y, Yamagata Y, Yamashita H, Nomura S, Seto Y. Mediastinoscopic view of the bronchial arteries in a series of surgical cases evaluated with three-dimensional computed tomography. Esophagus, 15:173-179, 2018